Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Silver Spur Therapeutics is a preclinical-stage biotechnology company spun out from the University of Southern California (USC). The company is developing a proprietary nanomedicine delivery platform utilizing peptide amphiphile micelles (PAMs) and collecting duct-targeted lipid nanoparticles (CD LNPs) to enable precise, tissue-specific delivery of small molecules and genetic therapeutics. Its primary therapeutic focus is on treating autosomal dominant polycystic kidney disease (ADPKD) and cardiovascular diseases like atherosclerosis. By targeting therapeutic agents directly to specific tissues, Silver Spur aims to maximize efficacy while reducing systemic toxicity and off-target effects.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Silver Spur Therapeutics.